Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Scorpius Holdings Inc (EM) SCPX

Scorpius Holdings, Inc., through its subsidiary Scorpius BioManufacturing, operates as an integrated contract development and manufacturing organization. The company engages in clinical and commercial drug substance manufacturing; and release and stability testing activities. It is also involved in the provision of various process development services, including upstream and downstream development and optimization, and analytical method development solutions, as well as cell line development, testing, and characterization services. The company serves the biotechnology and biopharmaceutical industries. The company was formerly known as NightHawk Biosciences, Inc. and changed its name to Scorpius Holdings, Inc. in February 2024. Scorpius Holdings, Inc. was incorporated in 2008 and is based in San Antonio, Texas.


EXPM:SCPX - Post by User

Post by ghayeson Nov 08, 2021 3:06pm
513 Views
Post# 34101464

anyone else following HTBX ?

anyone else following HTBX ?Anyone else got any insights into HTBX ? had a couple of run ups a year ago and 6 months ago, since then, it is just dithering around the low $5 range. I  look at their most advanced product pipleline item, HS110 a treatment for non-small cell lung cancer - and I see that the study isn't due to be completed until August 2022.A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer - Full Text View - ClinicalTrials.gov 
That is a while to wait.
Anyone give me some other reasons to get in at $5 now?
Otherwise I just see this drifting down to.. $5, $3, $2...?
Seems to be a good complany with some good products, but when are they going to deliver a breakthrough?  GLTA...
<< Previous
Bullboard Posts